Users Online: 1704 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 
 

 
Table of Contents
LETTER TO EDITOR
Year : 2018  |  Volume : 34  |  Issue : 4  |  Page : 548

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”


1 Global Medical Affairs, Pfizer Inc., New York, NY, USA
2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
3 Formerly of Pfizer Global Research and Development (Rinat), Pfizer Inc., South San Francisco, California, USA

Date of Web Publication3-Jan-2019

Correspondence Address:
Leslie A Tive
Pfizer Inc., 235 E 42nd St, New York, NY, 10017
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joacp.JOACP_155_18

Rights and Permissions

How to cite this article:
Tive LA, Viktrup L, Shelton D. Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”. J Anaesthesiol Clin Pharmacol 2018;34:548

How to cite this URL:
Tive LA, Viktrup L, Shelton D. Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”. J Anaesthesiol Clin Pharmacol [serial online] 2018 [cited 2019 May 25];34:548. Available from: http://www.joacp.org/text.asp?2018/34/4/548/249292



Madam,

We read with interest the recently published review article by Patel et al. titled “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.”[1] Tanezumab is under investigation for the treatment of osteoarthritis pain and chronic low back pain by Pfizer Inc. and Eli Lilly & Company. As Pfizer or Lilly were not involved or consulted regarding the content of this article, we would like to point out that the molecular formula of tanezumab presented in [Figure 1] is incorrect. For a more accurate representation of the structure of tanezumab, we refer readers to an article by La Porte et al.[2]

—On behalf of the tanezumab development team.

Financial support and sponsorship

Editorial support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and was funded by Eli Lilly & Co and Pfizer.

Conflicts of interest

Leslie Tive is a full-time employee of, and own stock and/or stock options in, Pfizer Inc. David Shelton is a consultant for, and owns stock in, Pfizer Inc. Lars Viktrup is a full-time employee of, and owns stock and/or stock options in, Eli Lilly & Company.



 
  References Top

1.
Patel MK, Kaye AD, Urman RD. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol 2018;34:111-6.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
La Porte SL, Eigenbrot C, Ultsch M, Ho WH, Foletti D, Forgie A, et al. Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized fab-antigen complexes. MAbs 2014;6:1059-68.  Back to cited text no. 2
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed285    
    Printed5    
    Emailed0    
    PDF Downloaded54    
    Comments [Add]    

Recommend this journal